The estimated Net Worth of Scott W Morrison is at least $1.07 Millón dollars as of 24 June 2024. Mr. Morrison owns over 3,350 units of Global Blood Therapeutics stock worth over $320,739 and over the last 9 years he sold GBT stock worth over $145,008. In addition, he makes $599,495 as Independent Director at Global Blood Therapeutics.
Sign up
Mr. Morrison GBT stock SEC Form 4 insiders trading
Scott has made over 6 trades of the Global Blood Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,350 units of GBT stock worth $229,442 on 24 June 2024.
The largest trade he's ever made was selling 4,800 units of Global Blood Therapeutics stock on 9 September 2021 worth over $145,008. On average, Scott trades about 498 units every 35 days since 2016. As of 24 June 2024 he still owns at least 4,683 units of Global Blood Therapeutics stock.
You can see the complete history of Mr. Morrison stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Morrison biography
Scott W. Morrison CPA serves as Independent Director of the Company. From 1996 to December 2015, Mr. Morrison was a partner at Ernst & Young LLP, a public accounting firm, and served as its U.S. Life Sciences Leader since 2002. He currently serves on the board of directors of Corvus Pharmaceuticals, Inc., a biopharmaceutical company and Ideaya Biosciences, Inc., a biotechnology company. Mr. Morrison served on the board and chaired the audit committee of Audentes, Inc. from December 2015 through its sale to Astellas Pharma Inc. in January 2020. Mr. Morrison has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center Board (now California Life Sciences Association), the California Life Sciences Foundation and the Biotechnology Institute. Mr. Morrison holds a B.S. in Accounting and Finance from the University of California, Berkeley and is a Certified Public Accountant (inactive). Mr. Morrison’s qualifications to serve on our Board of Directors include significant accounting expertise and knowledge of the life sciences industry through his 35-year career in public accounting serving public and private companies in the life sciences sector, as well as his experience serving on the board of directors (and certain key standing committees) of other biotechnology companies since 2015.
What is the salary of Scott Morrison?
As the Independent Director of Global Blood Therapeutics, the total compensation of Scott Morrison at Global Blood Therapeutics is $599,495. There are 14 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
How old is Scott Morrison?
Scott Morrison is 62, he's been the Independent Director of Global Blood Therapeutics since 2016. There are 5 older and 13 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
What's Scott Morrison's mailing address?
Scott's mailing address filed with the SEC is 15440 LAGUNA CANYON ROAD, SUITE 160, , IRVINE, CA, 92673.
Insiders trading at Global Blood Therapeutics
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... y Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
What does Global Blood Therapeutics do?
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
What does Global Blood Therapeutics's logo look like?
Complete history of Mr. Morrison stock trades at Corvus Pharmaceuticals Inc, Global Blood Therapeutics, Zai Lab, IDEAYA Biosciences y Tarsus Pharmaceuticals
Global Blood Therapeutics executives and stock owners
Global Blood Therapeutics executives and other stock owners filed with the SEC include:
-
Ted Love,
President, Chief Executive Officer, Director -
Brian Cathers,
Chief Scientific Officer -
Tricia Suvari,
Chief Legal Officer -
Jung Choi,
Chief Business and Strategy Officer -
David Johnson,
Chief Commercial Officer -
Jeffrey Farrow,
Chief Financial Officer -
Dr. Ted W. Love,
Pres, CEO & Director -
Dr. Ted W. Love M.D.,
Pres, CEO & Director -
David L. Johnson,
Chief Commercial Officer -
Jeffrey S. Farrow,
CFO & Principal Accounting Officer -
Jung E. Choi,
Chief Bus. & Strategy Officer -
Dr. Kim Smith-Whitley M.D.,
Exec. VP and Head of R&D -
Patricia Borga Suvari,
Chief Legal Officer & Sec. -
Mark Perry,
Lead Independent Director -
Scott Morrison,
Independent Director -
Wendy Yarno,
Independent Director -
Deval Patrick,
Director -
Glenn Pierce,
Independent Director -
Philip Pizzo,
Independent Director -
Willie Brown,
Independent Director -
Dawn Svoronos,
Independent Director -
Eric Fink,
Chief Human Resource Officer -
Stephanie Yao,
Sr. Director of Corp. Communications & Investor Relations -
Nazila Habibizad,
Exec. VP of Operations -
Dr. Andrej Sali Ph.D.,
Founder & Advisor -
Dr. Matthew P. Jacobson Ph.D.,
Founder & Advisor -
Dr. David R. Phillips,
Founder & Advisor -
Lesley Ann Calhoun,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Ii, L.P.Third...,
-
Michael W Bonney,
Director -
Eleanor Ramos,
Chief Medical Officer -
Kevin P Starr,
Director -
Charles J Homcy,
Director -
Robert I Tepper,
10% owner -
Rock Ventures Ii, L.P.Starr...,
-
Hing Sham,
See Remarks -
Joshua Lehrer Graiwer,
Chief Medical Officer -
Advisors Llcperceptive Life...,
-
Peter Radovich,
See Remarks -
Nazila Habibizad,
See Remarks -
John Schembri,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Iii, L.P.Thir...,
-
Carrie Krehlik,
Chief Human Resources Officer -
Alexis A. Thompson,
Director -
Kim Smith Whitley,
See Remarks